Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

96 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The potential for improving cardio-renal outcomes in chronic kidney disease with the aldosterone synthase inhibitor vicadrostat (BI 690517): a rationale for the EASi-KIDNEY trial.
Judge PK, Tuttle KR, Staplin N, Hauske SJ, Zhu D, Sardell R, Cronin L, Green JB, Agrawal N, Arimoto R, Mayne KJ, Sammons E, Brueckmann M, Shah SV, Rossing P, Nangaku M, Landray MJ, Wanner C, Baigent C, Haynes R, Herrington WG. Judge PK, et al. Among authors: staplin n. Nephrol Dial Transplant. 2024 Nov 12:gfae263. doi: 10.1093/ndt/gfae263. Online ahead of print. Nephrol Dial Transplant. 2024. PMID: 39533115
Long-Term Effects of Empagliflozin in Patients with Chronic Kidney Disease.
EMPA-KIDNEY Collaborative Group; Herrington WG, Staplin N, Agrawal N, Wanner C, Green JB, Hauske SJ, Emberson JR, Preiss D, Judge P, Zhu D, Dayanandan R, Arimoto R, Mayne KJ, Ng SYA, Sammons E, Hill M, Stevens W, Wallendszus K, Brenner S, Cheung AK, Liu ZH, Li J, Hooi LS, Liu W, Kadowaki T, Nangaku M, Levin A, Cherney DZI, Maggioni AP, Pontremoli R, Deo R, Goto S, Rossello X, Tuttle KR, Steubl D, Massey D, Brueckmann M, Landray MJ, Baigent C, Haynes R. EMPA-KIDNEY Collaborative Group, et al. Among authors: staplin n. N Engl J Med. 2024 Oct 25:10.1056/NEJMoa2409183. doi: 10.1056/NEJMoa2409183. Online ahead of print. N Engl J Med. 2024. PMID: 39453837 Free PMC article.
Combination of the chemokine receptor type 2 (CCR2) antagonist DMX-200 and candesartan for COVID-19: a randomised controlled trial.
O'Hara DV, Bassi A, Wilcox A, Jha V, Rathore V, D'Cruz S, Snelling TL, Jones M, Totterdell J, Bangi A, Jain MK, Pollock C, Burrell L, Fox G, Jones C, Kotwal S, Faridah Syed Omar S, Jardine M; CLARITY 2.0 trial investigators. O'Hara DV, et al. BMJ Open. 2024 Oct 22;14(10):e081790. doi: 10.1136/bmjopen-2023-081790. BMJ Open. 2024. PMID: 39438096 Free PMC article. Clinical Trial.
Empagliflozin lowers serum uric acid in chronic kidney disease: exploratory analyses from the EMPA-KIDNEY trial.
Mayne KJ, Sardell RJ, Staplin N, Judge PK, Zhu D, Sammons E, Cherney DZI, Green JB, Levin A, Pontremoli R, Hauske SJ, Emberson J, Preiss D, Landray MJ, Baigent C, Wanner C, Haynes R, Herrington WG; EMPA-KIDNEY Collaborative Group. Mayne KJ, et al. Among authors: staplin n. Nephrol Dial Transplant. 2024 Sep 14:gfae203. doi: 10.1093/ndt/gfae203. Online ahead of print. Nephrol Dial Transplant. 2024. PMID: 39277784 Free PMC article.
Sodium-glucose co-transporter-2 inhibitors for hospitalised patients with COVID-19: a prospective meta-analysis of randomised trials.
Vale C, Godolphin PJ, Fisher D, Horby PW, Kosiborod MN, Hochman JS, Webster K, Higgins JPT, Althouse AD, Berwanger O, Furtado RHM, Gasparyan SB, Haynes R, Koch GG, Landray M, Leifer E, Marshall J, Murthy S, Neal MD, Staplin N, Diaz J, Sterne JAC, Shankar-Hari M; WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group. Vale C, et al. Among authors: staplin n. Lancet Diabetes Endocrinol. 2024 Oct;12(10):735-747. doi: 10.1016/S2213-8587(24)00219-5. Epub 2024 Sep 6. Lancet Diabetes Endocrinol. 2024. PMID: 39250923 Free article.
Resistant Hypertension and Mortality: An Observational Cohort Study.
de la Sierra A, Ruilope LM, Staplin N, Gorostidi M, Vinyoles E, Segura J, Armario P, Oliveras A, Williams B. de la Sierra A, et al. Among authors: staplin n. Hypertension. 2024 Nov;81(11):2350-2356. doi: 10.1161/HYPERTENSIONAHA.124.23276. Epub 2024 Sep 9. Hypertension. 2024. PMID: 39247961
A global view on kidney care.
Staplin N. Staplin N. Nephrol Dial Transplant. 2024 Sep 5;39(Supplement_2):ii1-ii2. doi: 10.1093/ndt/gfae133. Nephrol Dial Transplant. 2024. PMID: 39235194 No abstract available.
Efficacy and safety of SGLT2 inhibitors with and without glucagon-like peptide 1 receptor agonists: a SMART-C collaborative meta-analysis of randomised controlled trials.
Apperloo EM, Neuen BL, Fletcher RA, Jongs N, Anker SD, Bhatt DL, Butler J, Cherney DZI, Herrington WG, Inzucchi SE, Jardine MJ, Liu CC, Mahaffey KW, McGuire DK, McMurray JJV, Neal B, Packer M, Perkovic V, Sabatine MS, Solomon SD, Staplin N, Szarek M, Vaduganathan M, Wanner C, Wheeler DC, Wiviott SD, Zannad F, Heerspink HJL. Apperloo EM, et al. Among authors: staplin n. Lancet Diabetes Endocrinol. 2024 Aug;12(8):545-557. doi: 10.1016/S2213-8587(24)00155-4. Epub 2024 Jul 8. Lancet Diabetes Endocrinol. 2024. PMID: 38991584
Frailty, multimorbidity and polypharmacy: exploratory analyses of the effects of empagliflozin from the EMPA-KIDNEY trial.
Mayne KJ, Sardell RJ, Staplin N, Judge PK, Zhu D, Sammons E, Cherney DZ, Cheung AK, Maggioni AP, Nangaku M, Rossello X, Tuttle KR, Ihara K, Iwata T, Wanner C, Emberson J, Preiss D, Landray MJ, Baigent FMedSci C, Haynes R, Herrington WG; EMPA-KIDNEY Collaborative Group. Mayne KJ, et al. Among authors: staplin n. Clin J Am Soc Nephrol. 2024 Jul 1;19(9):1119-29. doi: 10.2215/CJN.0000000000000498. Online ahead of print. Clin J Am Soc Nephrol. 2024. PMID: 38949880
96 results